GSK Advances Liver Disease Research and Biotech CEO Sisterhood Grows Influence
GSK Liver Disease Plans:
GSK has entered into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease1.
The partnership aims to deepen the understanding of liver biology and accelerate the development of medicines for liver diseases1.
GSK highlighted key data from its hepatology portfolio at the AASLD’s The Liver Meeting 2024, emphasizing patient impact in areas of high unmet need5.
Biotech CEO Sisterhood:
The Biotech CEO Sisterhood is a community dedicated to championing the success of women leaders in the biopharma industry23.
The Sisterhood hosts summits, local events, and educational sessions to encourage dialogue about challenges facing women in biotech and enhance leadership effectiveness23.
The group has grown to over 300 members since its inception in 2022 and has facilitated panels and partnered with organizations like BIO to advocate for women in biotech23.
JPM25 Updates:
GSK has also acquired IDRx for $1B to bring new standards of care to GIST patients4.
Other notable updates from JPM25 include J&J’s acquisition of Intra-Cellular for $14.6B and Biogen’s unsolicited takeover bid for Sage Therapeutics4.
Sources:
1. https://www.biospace.com/gsk-enters-into-a-multi-year-data-licence-agreement-with-ochre-bio-to-further-investigate-the-drivers-of-liver-disease
2. https://www.biotechtv.com/biotech-ceo-sisterhood
3. https://bio.news/diversity-equity-inclusion/biotech-sisterhood-csuite-ceo-biopharma-women-leadership-advocacy/
5. https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-key-data-from-hepatology-portfolio-at-the-aasld-s-the-liver-meeting-2024-emphasising-patient-impact-in-areas-of-high-unmet-need/